m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0175)
| Name |
Visual impairment
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 9D90
|
||||
Full List of Target Gene(s) of This m6A-centered Disease Response
Mammalian target of rapamycin complex 2 (mTORC2)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
| Response Summary | FTO regulates pathological ocular angiogenesis by controlling endothelial cell function in an m6A-YTHDF2-dependent manner. Pathological ocular angiogenesis commonly results in visual impairment or even blindness. | |||
| Responsed Disease | Vision impairment [ICD-11: 9D90] | |||
| Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
| In-vitro Model | HUVEC-C | Normal | Homo sapiens | CVCL_2959 |
| In-vivo Model | After general anesthesia with an intraperitoneal injection of ketamine (80 mg/kg) and xylazine (4 mg/kg), topical application of 0.5% proparacaine ophthalmic solution was conducted. Three sutures (10-0 nylon) were placed intrastromally between the limbus and corneal center at the 4, 8, and 12 o'clock positions. Topical norfloxacin was applied after surgery. | |||